Literature DB >> 25338186

Impact of severe oesophagogastric varices on liver resection for hepatocellular carcinoma in cirrhotic patients.

Hsiao-Tien Liu1, Shao-Bin Cheng, Cheng-Chung Wu, Hong-Zen Yeh, Chi-Sen Chang, John Wang.   

Abstract

BACKGROUND: The aim of the present study was to clarify both short-term and long-term results of patients with concomitant hepatocellular carcinoma (HCC) and high-risk oesophagogastric varices (OGV).
METHODS: This retrospective study identified 927 cirrhotic patients who underwent curative resection of HCC between 1995 and 2012 in single institution. Patients were separated into 3 groups (A, B, and C) according to general rules for recording endoscopic findings of oesophagogastric varices proposed in Japan in 1991. Groups A, B, and C consisted of patients without OGV (F0), patients with mild to moderate OGV (F1 to F2), and patients with high-risk OGV (F3 and/or red color sign), respectively. All patients in group C underwent prophylactic endoscopic variceal ligation/sclerotherapy. Post-operative complications, mortality, overall survival, and disease-free survival were compared among 3 groups.
RESULTS: No patient had post-operative variceal bleeding. Complication rates of Clavien-Dindo grade II to V in three groups were 13.6, 14.0, and 6.9 %, respectively (P > 0.05). Operative mortality, 5-year overall survival rate, and disease-free survival rate among the 3 groups were not significantly different (P > 0.05).
CONCLUSIONS: Prophylactic endoscopic variceal ligation/sclerotherapy effectively prevented from post-operative variceal bleeding in patients with high-risk OGV. Operative mortality, major morbidity, and survival of patients with high-risk OGV were similar to those of patients without OGV or those with mild OGV. Liver resection remains a feasible choice for cirrhotic patients with concomitant HCC and high-risk OGV.

Entities:  

Mesh:

Year:  2015        PMID: 25338186     DOI: 10.1007/s00268-014-2811-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  40 in total

1.  Delayed formation of gallstone after transcatheter arterial embolization for hepatocellular carcinoma. Is elective cholecystectomy advisable during hepatectomy?

Authors:  K S Jeng; H J Chiang
Journal:  Arch Surg       Date:  1989-11

Review 2.  General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?

Authors:  Masato Fujiki; Federico Aucejo; Richard Kim
Journal:  Liver Int       Date:  2011-09       Impact factor: 5.828

3.  Continuous versus intermittent portal triad clamping for liver resection: a controlled study.

Authors:  J Belghiti; R Noun; R Malafosse; P Jagot; A Sauvanet; F Pierangeli; J Marty; O Farges
Journal:  Ann Surg       Date:  1999-03       Impact factor: 12.969

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Treatment of concomitant gastric varices in patients with hepatocellular carcinoma at a single Japanese institute.

Authors:  Atsushi Nanashima; Yorihisa Sumida; Takafumi Abo; Kenichirou Shibata; Kouichi Tomoshige; Hiroaki Takeshita; Shigekazu Hidaka; Hidetoshi Fukuoka; Kouji Mochinaga; Terumitsu Sawai; Toru Yasutake; Takeshi Nagayasu
Journal:  Hepatogastroenterology       Date:  2009 May-Jun

7.  Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

Authors:  J Bruix; A Castells; J Bosch; F Feu; J Fuster; J C Garcia-Pagan; J Visa; C Bru; J Rodés
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

8.  Additional Hassab's operation for esophagogastric varices in cirrhotic patients with resectable hepatocellular carcinoma.

Authors:  Hiroyuki Sugo; Noriko Fujiwara; Jiro Yoshimoto; Ken Miwa; Yoichi Ishizaki
Journal:  Hepatogastroenterology       Date:  2008 Sep-Oct

9.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

10.  Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Norihiro Kokudo; Keiji Sano; Hiroshi Imamura; Yoshifumi Beck; Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2009-01
View more
  3 in total

Review 1.  Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-09-18

2.  Is it a time to modify the BCLC guidelines in terms of the role of surgery?

Authors:  Norihiro Kokudo
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

3.  Liver resection for hepatocellular carcinoma in patients with hematological malignancies.

Authors:  Hui-Chen Lin; Yang-Shen Yang; Chieh-Lin Jerry Teng; Ching-Hui Shen; Yee-Gee Jan; Shao-Bin Cheng; Cheng-Chung Wu; Yi-Ling Lin; Chu-Chun Huang; Fang-Ku P'eng
Journal:  World J Surg Oncol       Date:  2017-11-02       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.